ANDA 212071, held by Exela Pharma. Cupric Chloride.
As of Nov 16, 2026, ANDA 212071 (Cupric Chloride), held by Exela Pharma, was first approved by FDA on Oct 31, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cupric Chloride Injection, USP 0.4 mg/mL is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cupric ChlorideEQ 0.4MG COPPER/ML · injectable;injection | Cupric Chloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters